Migraine management in France: Practices of general practitioners and neurologists.

IF 2.8 4区医学 Q2 CLINICAL NEUROLOGY

Revue neurologique Pub Date : 2025-07-17 DOI:10.1016/j.neurol.2025.06.006

C Lucas, V Raclot, M Gugenheim, H Lefebvre, B Braithwaite, A Ducros

{"title":"Migraine management in France: Practices of general practitioners and neurologists.","authors":"C Lucas, V Raclot, M Gugenheim, H Lefebvre, B Braithwaite, A Ducros","doi":"10.1016/j.neurol.2025.06.006","DOIUrl":null,"url":null,"abstract":"Background: In 2024, despite updated French guidelines, migraine remains underdiagnosed and undertreated. We conducted a comprehensive survey to evaluate the management of migraine patients by French general practitioners (GPs) and neurologists, and to identify factors linked to low prescription rates of recommended treatments.Methods: A total of 320 GPs and 215 neurologists practicing in France were analyzed after completing an online questionnaire (between June and October 2023) regarding their prescribing behaviors and influencing factors, whose potential associations were analyzed statistically.Results: GPs most commonly prescribe triptans (71.6%) and non-steroidal anti-inflammatory drugs (NSAIDs, 66.6%) for acute migraine treatment, and propranolol (71.6%) as prophylaxis. Lower prescribing rates were associated with shorter practice duration, negative perceptions of risk-benefit and lack of recent migraine training. Conversely, recent migraine training significantly reduced low prescription rates of prophylactic treatments. Neurologists frequently prescribe triptans (93.5%) and NSAIDs (89.3%) for acute treatment, as well as propranolol (76.3%) and amitriptyline (61.4%) as prophylaxis. The prescription of newer treatments like calcitonin gene-related peptide monoclonal antibodies is limited, with only 7.0% of respondents frequently using them.Conclusion: While GPs and neurologists often use recommended acute treatments, prophylactic and newer therapies are less commonly prescribed, despite recently updated French guidelines on migraine management.","PeriodicalId":21321,"journal":{"name":"Revue neurologique","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue neurologique","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.neurol.2025.06.006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In 2024, despite updated French guidelines, migraine remains underdiagnosed and undertreated. We conducted a comprehensive survey to evaluate the management of migraine patients by French general practitioners (GPs) and neurologists, and to identify factors linked to low prescription rates of recommended treatments.

Methods: A total of 320 GPs and 215 neurologists practicing in France were analyzed after completing an online questionnaire (between June and October 2023) regarding their prescribing behaviors and influencing factors, whose potential associations were analyzed statistically.

Results: GPs most commonly prescribe triptans (71.6%) and non-steroidal anti-inflammatory drugs (NSAIDs, 66.6%) for acute migraine treatment, and propranolol (71.6%) as prophylaxis. Lower prescribing rates were associated with shorter practice duration, negative perceptions of risk-benefit and lack of recent migraine training. Conversely, recent migraine training significantly reduced low prescription rates of prophylactic treatments. Neurologists frequently prescribe triptans (93.5%) and NSAIDs (89.3%) for acute treatment, as well as propranolol (76.3%) and amitriptyline (61.4%) as prophylaxis. The prescription of newer treatments like calcitonin gene-related peptide monoclonal antibodies is limited, with only 7.0% of respondents frequently using them.

Conclusion: While GPs and neurologists often use recommended acute treatments, prophylactic and newer therapies are less commonly prescribed, despite recently updated French guidelines on migraine management.

查看原文本刊更多论文

偏头痛在法国的管理：全科医生和神经科医生的做法。

背景：2024年，尽管法国更新了指南，但偏头痛仍未得到充分诊断和治疗。我们进行了一项全面的调查，以评估法国全科医生（gp）和神经科医生对偏头痛患者的管理，并确定与推荐治疗的低处方率相关的因素。方法：对法国320名全科医生和215名神经科医生在2023年6月至10月期间填写的处方行为及影响因素在线问卷进行分析，并对其潜在关联进行统计分析。结果：全科医生最常开曲坦类药物（71.6%）和非甾体抗炎药（NSAIDs, 66.6%）治疗急性偏头痛，预防用药为心得安（71.6%）。较低的处方率与较短的实践时间、对风险-收益的负面看法以及近期缺乏偏头痛训练有关。相反，最近的偏头痛训练显著降低了预防性治疗的低处方率。神经科医生经常在急性治疗中使用曲坦类药物（93.5%）和非甾体抗炎药（89.3%），以及普萘洛尔（76.3%）和阿米替林（61.4%）作为预防。降钙素基因相关肽单克隆抗体等新疗法的处方有限，只有7.0%的受访者经常使用。结论：虽然全科医生和神经科医生经常使用推荐的急性治疗方法，但预防性和较新的治疗方法很少被开处方，尽管法国最近更新了偏头痛治疗指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revue neurologique 医学-临床神经学

CiteScore

4.80

自引率

0.00%

发文量

598

审稿时长

55 days

期刊介绍： The first issue of the Revue Neurologique, featuring an original article by Jean-Martin Charcot, was published on February 28th, 1893. Six years later, the French Society of Neurology (SFN) adopted this journal as its official publication in the year of its foundation, 1899. The Revue Neurologique was published throughout the 20th century without interruption and is indexed in all international databases (including Current Contents, Pubmed, Scopus). Ten annual issues provide original peer-reviewed clinical and research articles, and review articles giving up-to-date insights in all areas of neurology. The Revue Neurologique also publishes guidelines and recommendations. The Revue Neurologique publishes original articles, brief reports, general reviews, editorials, and letters to the editor as well as correspondence concerning articles previously published in the journal in the correspondence column.